Glycogen phosphorylase (GP) is a pivotal enzyme responsible for the catabolism of glycogen into glucose, a process intricately linked to blood glucose regulation. In the context of type 2 diabetes, ...

An analysis of real-world data from a single medical center is providing insight into the effects of off-label glucagon-like peptide 1 (GLP-1) receptor agonist (RA) and sodium-glucose cotransporter-2 ...

ASCO 2021 brings us news of RELATIVITY-047, which tested the combination of anti-PD-1 nivolumab with a drug called relatlimab that is an inhibitor of the lymphocyte activation gene-3 (LAG-3) pathway.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio NEW ORLEANS — A novel “counterintuitive” ...

A Janus kinase (JAK) inhibitor helped preserve beta-cell function in people with recent-onset type 1 diabetes, the phase II BANDIT trial found. Meeting the study's primary endpoint, daily baricitinib ...

Molecular Tumor Board–Assisted Care in an Advanced Cancer Population: Results of a Phase II Clinical Trial The development of the selective RET inhibitors selpercatinib and pralsetinib has ...

KDM5 inhibition/disruption selectively induces R-loop-mediated DNA damage and innate immune activation in breast cancer cells, while sparing normal cells, unveiling a tumor-specific therapeutic ...

A new-generation KRAS G12C inhibitor induced responses in more than half of patients with previously treated non-small cell lung cancer (NSCLC) harboring the mutation, a subgroup analysis of a phase I ...